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Abstract: The involvement of epigenetic aberrations in the development and progression 
of tumors is now well established. However, most studies have focused on the epigenetic 
inactivation of tumor suppressor genes during tumorigenesis and little is known about the 
epigenetic activation of cancer-associated genes, except for the DNA hypomethylation of 
some genes. Recently, we reported that the overexpression of cancer-promoting genes in 
ovarian  cancer  is  associated  with  the  loss  of  repressive  histone  modifications.  This 
discovery suggested that epigenetic derepression may contribute to ovarian tumorigenesis 
by  constituting  a  possible  mechanism  for  the  overexpression  of  oncogenes  or  
cancer-promoting genes in tumors. The emerging importance of epigenetic aberrations in 
tumor initiation and in the regulation of cancer-initiating cells, suggests that epigenetically 
regulated  genes  may  be  promising  therapeutic  targets  and  biomarkers.  Given  that  the 
current  challenges  in  ovarian  cancer  include  the  identification  of  biomarkers  for  early 
cancer detection and the discovery of novel therapeutic targets for patients with recurrent 
malignancies undergoing chemotherapy, understanding the epigenetic changes that occur 
in ovarian cancer is crucial. This review looks at epigenetic mechanisms involved in the 
regulation of cancer-associated genes, including the contribution of epigenetic derepression 
to  the  activation  of  cancer-associated  genes  in  ovarian  cancer.  In  addition,  possible 
epigenetic  therapies  targeting  epigenetically  dysregulated  genes  are  discussed.  A  better 
understanding  of  the  epigenetic  changes  in  ovarian  cancer  will  contribute  to  the 
improvement of patient outcomes.  
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1. Introduction  
Ovarian  cancer  is  the  most  lethal  gynecological  malignancy  [1].  Due  to  difficulties  in  early 
detection,  most  ovarian  cancers  are  diagnosed  at  an  advanced  stage.  Furthermore,  most  patients 
diagnosed at an advanced stage show a poor prognosis because recurrence occurs in the majority of 
patients,  although  most  respond  to  current  standard  chemotherapies  [2].  Therefore,  a  better 
understanding of the molecular pathogenesis of ovarian cancer is required so that novel biomarkers 
facilitating early detection and the development of new therapeutic targets are identified. 
Ovarian cancers are very heterogeneous at the clinical, histopathological and molecular levels [3]. 
More than 90% of ovarian cancers are epithelial in origin and are thought to arise from the ovarian 
surface epithelium (OSE) or from surface epithelial inclusion cysts [3,4]. As is well known in other 
forms of human tumorigenesis, epithelial ovarian cancers are caused by both multiple genetic and 
epigenetic  alterations  [4].  They  develop  due  to  the  accumulation  of  genetic  changes  in  multiple 
oncogenes  and  tumor  suppressors.  These  genetic  changes  drive  alterations  in  cellular  signaling 
pathways that are some of the hallmarks of cancer and contribute to ovarian tumorigenesis [4]. To date, 
more than 15 oncogenes and 16 putative tumor suppressor genes have been implicated in ovarian 
oncogenesis [4]. The most well-known tumor suppressor genes that are frequently lost or inactivated in 
epithelial ovarian cancer include TP53, PTEN, BRCA1 and BRCA2. Commonly activated oncogenes 
are KRAS, BRAF, and PIK3CA. In addition, several signaling pathways are frequently activated in 
ovarian cancer, including the Ras-MAPK signaling pathway, the PI3K pathway, IL6-IL6R-Jak2-STAT3 
signaling, and the LPA and NF-kB signaling pathways, amongst others [2,4]. Based on these genetic 
aberrations,  several  potential  anti-cancer  targets  have  been  identified  recently  and  novel  targeted 
therapeutics are under development [2,5]. The main focus of current targeted therapies is the inhibition 
of the oncogenes or signaling pathways that are most frequently activated or overexpressed in ovarian 
cancer and, which, it is assumed, provide synthetic lethality. However, given that the prevention of 
tumor recurrence after therapy is one of the main challenges in the treatment of ovarian cancer, and 
that  cancer-initiating  cells  (CICs)  may  be  involved  in  drug  resistance,  the  development  of  novel 
molecules  or  approaches  targeting  CICs  is  very  important.  Recent  studies  have  proposed  that 
epigenetic changes play a central role during the early stages of tumorigenesis and in the regulation of 
CICs [6,7]. Moreover, it is generally held that the activation of oncogenes occurs through genetic 
changes, including amplification and mutation, whereas tumor suppressor genes are inactivated by 
events  such  as  promoter  methylation,  gene  deletion  and  loss  of  heterozygosity  (LOH).  However, 
genetic changes such as gene amplification and mutation alone are insufficient to explain the activation 
of oncogenes or cancer-promoting genes in ovarian cancer, and the possible role of an epigenetic 
mechanism in the activation of cancer-associated genes has been suggested recently, although it is 
little understood [8].  Int. J. Mol. Sci. 2011, 12                       
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Despite the assumed importance of epigenetics in ovarian carcinogenesis, as in other malignancies, 
epigenetic aberrations that contribute to ovarian carcinogenesis or epigenetic mechanisms that regulate 
cancer-associated  genes  are  less  well  understood  than  are  genetic  changes.  Therefore,  this  review 
examines the current understanding of epigenetic mechanisms involved in the regulation of ovarian 
cancer-associated  genes,  including  oncogenes  and  tumor  suppressor  genes,  as  well  as  epigenetic 
abnormalities that contribute to ovarian tumorigenesis.  In addition, epigenetic therapies that target 
CICs,  or  drug  resistant  ovarian  cancers,  are  discussed  as  promising  approaches  for  the  efficient 
treatment of ovarian cancer.  
2. Epigenetic Changes in Cancer  
It has long been known that cancers are caused by genetic alterations [9]. A number of genetic 
changes  in  oncogenes,  including  mutations,  deletions,  amplifications,  rearrangements  and 
translocations, as well as changes in tumor suppressor or microRNA (miRNA) genes, are involved in 
multistep carcinogenesis, and accumulate with tumor progression [10,11]. However, classical genetics 
alone  cannot  explain  all  the  properties  of  cancer,  and  it  is  now  understood  that  epigenetic 
abnormalities, in addition to genetic alterations, are involved in tumorigenesis [12]. Epigenetics is 
defined as heritable changes in gene expression that are not caused by DNA sequence alterations [12]. 
Epigenetic  modifications  include  DNA  methylation  and  histone  modifications,  which  may  differ 
between cancer and normal cells [11,12]. Recently, small non-coding miRNAs were reported to act as 
epigenetic regulators. Such miRNAs regulate gene expression through posttranscriptional silencing of 
target genes. Depending on the sequence complementarity between the miRNA and its target, miRNAs 
lead to cleave the mRNA or inhibit translation [13]. Changes in the expression of miRNAs during 
tumorigenesis were discovered in several cancers and they are associated with the prognosis and the 
progression of cancer in some cases.  
DNA  methylation  is  a  well-known  epigenetic  mark.  In  humans  and  other  mammals, 
DNA methylation  occurs  at  cytosine  residues  in  cytosine-guanine  (CpG)  dinucleotides  and  is 
controlled by enzymes called DNA methytransferases (DNMTs), including DNMT1, DNMT3A and 
DNMT3B.  CpG  sites  are  mainly  distributed  in  CpG-rich  regions,  known  as  CpG  islands.  Most 
CpG islands are located in repetitive elements, such as centromeres, microsatellite sequences and the 
proximal promoter regions of approximately half of the genes in the genome of normal cells, where the 
islands are generally unmethylated [11]. 
The  transcriptional  inactivation  of  tumor  suppressor  genes  by  CpG  island  promoter 
DNA hypermethylation is well-known as one of the alterations that contributes to tumorigenesis in 
cancer cells [12]. At the same time, the genome of cancer cells undergoes global hypomethylation at 
repetitive  sequences,  or  in  tissue-specific  or  imprinted  genes,  whereas  these  regions  are  heavily 
hypermethylated  in  normal  cells  [14].  It  is  speculated  that  this  global  DNA  hypomethylation 
contributes to tumorigenesis by causing chromosomal instability or the reactivation of transposable 
elements [12,14]. On the other hand, the first study showing the endogenous repeat element-driven 
activation  of  the  oncogenic  tyrosine  kinase,  CSF1R,  was  recently  reported  [15],  suggesting  that 
impaired epigenetic control and the subsequent transcriptional derepression of repeat elements play a 
role  in  tumorigenesis.  This  study  further  demonstrated  that  oncogenes  can  be  activated  by  the Int. J. Mol. Sci. 2011, 12                       
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derepression  of  endogenous  repeats,  in  addition  to  genetic  and  epigenetic  modifications.  Loss  of 
imprinting  (LOI),  which  is  involved  in  the  development  of  tumors,  is  also  associated  with  DNA 
hypomethylation [12]. Furthermore, it has also been suggested that the activation of normally silenced 
genes by promoter DNA hypomethylation is involved in tumorigenesis [14]. 
In addition to DNA methylation, histone modifications are epigenetic marks that are involved in 
chromatin structure and gene expression. The so-called ―histone code‖ hypothesis posits that covalent 
modifications of histone tail residues act in concert to govern DNA packaging and thus regulate the 
access  of  transcriptional  machinery  to  coding  sequences  [16,17].  Histone  modifications  occur  at 
histone  residues,  such  as  lysine,  arginine  and  serine  (which  can  be  methylated,  acetylated  and 
phosphorylated) and in particular, the histone methylation and acetylation status of specific lysine 
residues has been correlated with either active or repressive transcription [14,18]. Specifically, the 
trimethylation  of  histone  H3  lysine  9  (H3K9me3),  H3  lysine  27  (H3K27me3)  and  H4  lysine 
20 (H4K20me3), in addition to H3K9 dimethylation (H3K9me2), facilitates transcriptional repression, 
whereas histone acetylation of histone H3 (H3Ac) and H4 (H4Ac), and the trimethylation of H3 lysine 
4 (H3K4me3) are associated with transcriptional activation. The methylation of specific histone lysine 
residues is mediated by their cognate histone methyltransferases, and the recent discovery of histone 
lysine demethylases has indicated that the so-called ―histone code‖ is highly signal-responsive and 
dynamic  [18,19].  In  embryonic  stem  cells,  the  ―bivalent‖  colocalization  of  activating  H3K4 
methylation and the repressive H3K27 methylation of development-associated genes, followed by the 
lineage-specific  loss  of  H3K4me3  or  H3K27me3,  has  been  reported  to  allow  differentiated  tissue 
silencing  or  expression  [20,21].  Furthermore,  a  growing  body  of  evidence  suggests  that  gene 
expression may be regulated by interactions between multiple histone modifications or by crosstalk 
between DNA methylation and histone modifications [22–24]. In particular, histone H3K9 methylation 
and H3K27 methylation (mediated by the polycomb repressive complex 2 (PRC2) protein, EZH2) are 
linked  to  DNA  methylation,  as  has  been  reported  in  several  studies  [22,25–27].  In  fact,  histone 
modifying enzymes such as histone deacetylase 1 (HDAC1) and HDAC2 were shown to interact with 
DNMT1 [28,29]. Moreover, heterochromatin protein, HP1, which binds H3K9 methylated histones, 
also cooperates with DNMT1 in mediating gene silencing [30]. EZH2, a component of PRC2, also 
binds directly to DNMTs [27] and the human polycomb-group protein (PcG), EED, was shown to 
interact with HDAC proteins [31]. Aberrant histone modifications, in addition to DNA methylation, 
are  recognized  as  important  epigenetic  changes  during  tumorigenesis.  While  the  promoters  of  
tumor-suppressor genes are enriched with active histone marks in normal cells, the transcriptional 
silencing of those genes in cancer cells is reported to be associated with a loss of active histone marks, 
including H3K4me3 and histone acetylation, and a gain of repressive H3K9 methylations, H4K20me3 
and  H3K27me3  marks  [14].  Moreover,  the  global  loss  of  acetylation  at  histone  H4K16  and  the 
trimethylation of H4K20 were shown to be common features of human cancer cells [32]. 
Although  not  as  well-established  as  the  epigenetic  regulators  of  DNA  methylation  and  histone 
modifications, the recently discovered miRNAs are also thought to play a role in tumorigenesis by 
modulating tumor suppressor genes or oncogenes [13,33]. miRNAs might contribute to tumorigenesis 
by  controlling  various  biological  processes,  including  differentiation,  proliferation,  and  apoptosis 
through regulation of or interactions with oncogenes or tumor suppressor genes. miRNAs can  act 
either as an oncogene or tumor suppressor gene depending on their target genes [13,33].  Int. J. Mol. Sci. 2011, 12                       
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Up-regulation of miRNAs that target tumor suppressor genes through overexpression, amplification, 
or epigenetic derepression might function as oncogenes by inhibiting the activity of an anti-oncogenic 
pathway. By contrast, the genetic mutation, deletion or epigenetic silencing of a tumor suppressor 
miRNA that normally represses expression of oncogenes might result in derepression of oncogenes, 
thereby gain of oncogenic function. The let-7 miRNAs, for example, which are down-regulated in lung 
cancer, negatively regulate the oncogenes RAS [34] and HMGA2 [35], suggesting their possible role in 
the activation of oncogenes in lung cancer. In addition, the oncogene c-Myc was shown to be a target 
of let-7a in lymphoma cells [36], while miR-15a and miR-16-1 function as tumor suppressors by 
targeting BCL2 in leukemia cells [37]. In contrast, miR-21 is up-regulated in several tumors and plays 
an  oncogenic  role  by  regulating  the  expression  of  the  tumor  suppressor  PTEN  in  hepatocellular 
cancer [38]. miRNAs expression can also be transcriptionally activated or repressed through direct 
interaction  with  oncogene  or  tumor  suppressor  transcription  factors.  miR-34  was  revealed  to  be 
induced by TP53 through direct binding of TP53 to the miR-34s, suggesting that TP53’s effects could 
be  mediated  in  part  by  transcriptional  activations  of  miRNAs  [39–41].  c-myc  was  also  shown  to 
transactivate  miRNAs  such  as  miR-17–92  cluster  [42],  while  it  represses  transcription  of  tumor 
suppressor miRNAs such as let-7 and miR-29 family members [43]. These data suggest that miRNAs 
play important roles in the oncogenic pathways through the regulation of multiple targets or mediation 
of oncogenic signals. Therefore, the discovery of key miRNAs that have multiple targets which are 
involved  in  different  oncogenic  pathways  or  that  are  mediators  of  oncogenic  pathways  might  be 
important in the development of effective anti-cancer drugs. On the other hand, miRNAs can directly 
modulate epigenetic regulatory mechanisms by targeting enzymes responsible for DNA methylation 
(DNMT3A and DNMT3B) [44] and histone modifications (EZH2) [45].  
In addition to the role of miRNAs in the development of tumors, miRNAs have been implicated in 
tumor progression by affecting adhesion, migration and invasion of cancer cells. miR-10b, a direct 
target of Twist 1, was up-regulated in metastatic breast cancer cells and ectopic miR-10b expression in 
non-metastatic breast cancer induced invasion and metastasis [46]. miR-373 and miR-520c were also 
shown to positively regulate cancer cell migration and invasion by blocking the adhesion molecule 
CD44 in breast cancer [47].  
3. Epigenetic Inactivation of Tumor Suppressor Genes or Cancer-Associated Genes in 
Ovarian Cancer  
It is well known that mutations in TP53, the most frequently mutated gene in cancer, result in  
loss-of-function, and that the loss of BRCA1 or BRCA2 function occurs through LOH or mutations [4]. 
It is also known that PTEN is inactivated by somatic mutations in ovarian cancer.  
In  addition  to  this  genetic  inactivation  of  tumor  suppressor  genes,  epigenetic  mechanisms  also 
contribute to the inactivation or down-regulation of tumor suppressor genes or cancer-associated genes 
in  ovarian  cancer  (Table  1).  For  example,  PTEN,  inactivated  by  LOH  and  mutation,  is  also  
down-regulated  by  promoter  DNA  methylation  [48].  In  addition,  it  was  recently  reported  that 
deregulated miR-214 targeted the 3’ UTR region of PTEN resulting in the down-regulation of the 
PTEN protein expression [49]. These findings suggest that several epigenetic changes are involved in Int. J. Mol. Sci. 2011, 12                       
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the down-regulation of PTEN in ovarian cancer. BRCA1 inactivation in ovarian cancer has also been 
associated with promoter DNA methylation, in addition to mutation and LOH [50].  
Loss of expression of the  growth inhibitory imprinted  genes, DIRAS3 (ARH1)  and PEG3, also 
occurs through promoter DNA methylation, in addition to LOH [51]. Several other putative tumor 
suppressor genes including RASSF1, DLEC1, CDKN2A, CDKN1A and MLH1 are also down-regulated 
by  promoter  methylation  or  histone  modifications  (Table  1).  In  particular,  repressive  histone 
methylation, H3K27me3, was shown to be responsible for RASSF1 down-regulation in ovarian cancer 
cells [25]. In addition, repression of ADAM19, a SMAD target gene, has been associated with the 
repressive histone modifications, H3K27me3 and H3K9me2, and histone deacetylase in ovarian cancer 
cells,  while  the  promoter  of  ADAM19  was  unmethylated  [52].  The  decreased  expression  of 
GATA transcription factors (GATA4 and GATA6) in ovarian cancer was found to correlate with the 
hypoacetylation of H3 and H4 and the loss of active H3K4me3. The genes could be reactivated by 
HDAC inhibitors, but not by DNA demethylating agents, suggesting that altered histone modifications, 
independent  of  DNA  methylation,  is  one  possible  mechanism  responsible  for  silencing  the 
GATA transcription factors in ovarian carcinogenesis [53]. 
The aberrant expression of miRNAs in ovarian cancer compared to normal ovaries was found in 
several studies [49,54,55]. Among significantly deregulated miRNAs, miR-200a [49,54], miR-200c 
and miR-141 [54,55] were the most strongly up-regulated and their higher expression was significantly 
associated with poor prognosis in ovarian cancer [55]. Some among the up-regulated miRNAs were 
also shown to be capable of acting as oncogenes by repressing expression of tumor suppressor genes. 
For example,  as  mentioned  above,  miR-214  functions  as  an  oncogene  by  targeting  the  tumor 
suppressor PTEN in ovarian  cancer cells.  It induced cell survival and cisplatin resistance through 
activation of Akt pathway by down-regulation of PTEN protein [49]. In addition, an increase in the 
expression of miR-200 family members correlated with the decreased expression of ZEB transcription 
factors,  which  are  known  to  promote  epithelial-mesenchymal  transition  (EMT)  by  repressing  the 
expression  of  critical  adhesion  molecules  of  epithelial  cells  and  miR-200  family  targets  ZEB1/2, 
suggesting that miR-200 family plays a role in ovarian tumor progression [56]. 
Table 1. Epigenetically down-regulated genes in ovarian cancer. 
Gene Symbol  Gene name  Chromosome   Mechanism of Down-Regulation   Reference  
Tumor Suppressor Genes Down-Regulated by Both Genetic and Epigenetic Changes  
PTEN  Phosphatase and tensin 
homolog  
10q23  LOH, mutation  [4] 
Promoter DNA methylation   [48] 
miRNA (miR-214)  [49] 
BRCA1  Breast cancer 1, early onset   17q21  Mutation, LOH  [4] 
Promoter DNA methylation  [50] 
OPCML  Opioid binding protein/cell 
adhesion molecule-like 
11q25  LOH, mutation  [4] 
Promoter DNA methylation  [57] 
DIRAS3 (ARHI)  DIRAS family, GTP-binding 
RAS-like 3 
1p31  Imprinting, LOH, promoter DNA 
methylation 
[51,58] 
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Table 1. Cont. 
      Transcription down-regulated by E2F1 
and E2F4 
[4] 
PEG3  Paternally expressed 3  19q13  Imprinting, LOH, promoter DNA 
methylation  
[51]  
TES *  Testis-derived 
transcript (3 LIM 
domains) 
7q31.2  LOH, promoter DNA methylation   [59,60]  
MYO18B *  Myosin XVIIIB   22q12.1  Mutation, promoter DNA methylation  [61] 
   
Tumor Suppressor Genes Down-Regulated By Epigenetic Changes   
RASSF1 
(RASSF1A) 
Ras association 
(RalGDS/AF-6) 
domain family 
member 1 
3p21  Promoter DNA methylation  [62] 
Histone methylation (H3K27me3)  [25] 
DLEC1  Deleted in lung and 
esophageal cancer 1 
3p22.3  Promoter DNA methylation, histone 
hypoacetylation 
[63] 
ARL11 (ARLTS1)  ADP-ribosylation 
factor-like 11  
13q.14  Promoter DNA methylation  [64] 
CDKN2A(p16)  Cyclin-dependent 
kinase inhibitor 2A 
(melanoma, p16, 
inhibits CDK4) 
9p21  Promoter DNA methylation  [65,66]  
CDKN1A(p21)  Cyclin-dependent 
kinase inhibitor 1A 
(p21, Cip1) 
6p21.2  Hypoacetylation of H3Ac and H4Ac  [67] 
MLH1(hMLH1)  MutL homolog 1, 
colon cancer, 
nonpolyposis type 2 
(E. coli) 
3p21.3  Promoter DNA methylation  [68,69]  
DAK(DAK1)  Death-associated 
protein kinase 1 
11q12.2  Promoter DNA methylation   [70] 
CDH1(E-cadherin)  Cadherin 1, type 1, E-
cadherin (epithelial) 
16q22.1  Promoter DNA methylation   [71] 
FBXO32  F-box protein 32   8q24.13  Promoter DNA methylation  [72] 
CTGF *  Connective tissue 
growth factor 
6q23.1  Promoter DNA methylation  [73] 
ANGPTL2 *  Angiopoietin-like 
protein 2 
9q33.3  Promoter DNA methylation  [74] 
Cancer-Associated Genes Down-Regulated By Epigenetic Changes     
ICAM1  Intercellular adhesion 
molecule 1 
19p13.3–p13.2  Promoter DNA methylation   [75]  
PCSK6 (PACE4)  Proprotein convertase 
subtilisin/kexin type 6 
15q26.3  Promoter DNA methylation and histone 
deacetylation 
[76] 
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Table 1. Cont. 
GATA4, GATA6  GATA binding protein 
4 GATA binding 
protein 6 
8p23.1–p22 
18q11.1–q11.2 
Hypoacetylation of H3Ac and H4Ac, 
loss of H3K4me3 
[53] 
ADAM19  ADAM 
metallopeptidase 
domain 19  
5q33.3  Repressive histone modifications 
(H3K27me3 and H3K9me2) 
[52] 
ZEB1  Zinc finger E-box 
binding homeobox 1 
10p11.2  miRNA (miR-200 family)  [56] 
ZEB2  Zinc finger E-box 
binding homeobox 2 
2q22.3  miRNA (miR-200 family)  [56] 
* putative or candidate tumor suppressor genes. LOH, loss of heterozygosity.  
4. Epigenetic Derepression of Oncogenes or Cancer-Promoting Genes in Ovarian Cancer  
It is generally known that oncogenes are activated or overexpressed by genetic alterations, including 
mutations or gene amplifications. In ovarian cancer, activating mutations in oncogenes such as KRAS, 
BRAF and PIK3CA  are common in low-grade (type I) ovarian tumors, while TP53 mutations are 
frequent in high-grade (type II) ovarian tumors [3]. However, a few oncogenes have been reported to 
be activated by spontaneous mutations in ovarian cancer, and gene amplifications alone cannot explain 
the  activation  or  overexpression  of  oncogenes,  although  their  frequency  is  higher  than  activating 
mutations [4]. These observations support the possibility that other mechanisms may be responsible for 
the activation of oncogenes in ovarian cancer.  
Unlike the well-known epigenetic silencing of tumor suppressor genes, the epigenetic activation of 
oncogenes or cancer-promoting genes is not well established. However, a growing number of recent 
findings  support  the  theory  that  epigenetic  mechanisms  may  promote  cancer  progression  by  the 
activation or overexpression of oncogenes or cancer-promoting genes in ovarian cancer as well as by 
the inactivation of tumor suppressor genes (Figure 1). 
4.1. Activation of Oncogenes or Cancer-Promoting Genes by DNA Hypomethylation  
In addition to global DNA hypomethylation, promoter DNA hypomethylation contributes to the 
activation of genes that are normally repressed in cancer cells. In ovarian cancer, it has been reported 
that  the  following  cancer-promoting  genes  are  overexpressed  in  association  with  promoter 
DNA hypomethylation: SNGG (synucelin-), encoding an activator of the MAPK and Elk-1 signaling 
cascades [77,78], BORIS (brother of the regulator of imprinted sites), a cancer-testis antigen gene and a 
paralog of CTCF [79] (Table 2). On the other hand, possible regulation of other cancer-germline (CG) 
or cancer-testis antigen  genes  by  BORIS  was  recently investigated but it was  shown that BORIS 
expression is not sufficient for induction of CG antigen gene expression and DNA hypomethylation in 
their  promoter  in  ovarian  cell  lines,  suggesting  the  involvement  of  additional  mechanisms  in  the 
regulation of CG antigen expression in ovarian cancer [80]. Other cancer-associated genes including 
MCJ  [81,82],  MAL  (mal,  T-cell  differentiation  protein)  [83],  HOXA10  [84]  and  TUBB3  [85]  are  
up-regulated in ovarian cancer in association with DNA hypomethylation. Int. J. Mol. Sci. 2011, 12                       
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Figure 1. Epigenetic regulation of cancer-associated genes in ovarian cancer. In addition to 
the  down-regulation  of  tumor  suppressor  genes  by  epigenetic  inactivation,  epigenetic 
derepression through DNA hypomethylation, loss of repressive histone modifications and 
gain of active histone modifications, together with down-regulated tumor suppressor (TS) 
miRNAs may contribute to ovarian carcinogenesis by the up-regulation of oncogenes or 
cancer-promoting genes. OncomiRNAs are miRNAs which act as oncogenes. 
 
4.2. Activation of Oncogenes or Cancer-Promoting Genes by Chromatin Modification  
In addition to DNA hypomethylation, epigenetic derepression by histone modification is a possible 
mechanism underlying the overexpression of cancer-promoting genes, although DNA hypomethylation 
has  been  mainly  reported  as  an  epigenetic  mechanism  underlying  the  up-regulation  of  
cancer-associated  genes. Recently, we  showed that the overexpression of claudin-3 and  claudin-4, 
which promote ovarian cell invasion, is associated with epigenetic derepression through the loss of 
repressive histone modifications, suggesting that changes in histone modifications can also contribute 
to the activation of cancer-promoting genes, independently of DNA methylation [86]. 
4.3. Regulation of Oncogenes or Cancer-Promoting Genes by miRNAs in Ovarian Cancer  
Deletion,  mutation  or  epigenetic  silencing  of  miRNAs  can  also  lead  to  the  overexpression  of 
oncogenes or cancer-promoting genes [33]. An integrated approach to epithelial ovarian cancer found 
that  miRNAs  were  down-regulated  in  advanced  ovarian  tumors  by  both  genomic  copy  number  loss 
(~15%)  and  epigenetic  silencing  (>36%),  and  that  down-regulated  miRNAs  contributed  to 
transcriptional deregulation [87]. Among significantly down-regulated miRNAs in ovarian cancer, the 
most strongly down-regulated miRNAs include miR-125b [49,54,55] and the let-7 family [49,88].  
With respect to the regulation of specific oncogenes or cancer-promoting genes by miRNAs in 
ovarian cancer, it was reported that miR-15a and miR-16 control oncogenic Bmi-1 expression as well 
as targeting anti-apoptotic Bcl-2 in ovarian cancer cell lines [89], while miR-9, was found to inhibit 
ovarian  cancer  growth  by  regulating  NF-kB1  expression  [90].  In  addition,  miR-125b  targets  Int. J. Mol. Sci. 2011, 12                       
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proto-oncogenic  BCL3,  which  can  suppress  ovarian  cancer  cell  growth  [91],  and  overexpressed 
ARID3B in ovarian cancer is a target of miR-125a [92]. Specifically, as ARID3B is involved in the 
mesenchymal phenotype development, ARID3B increase by repression of miR-125a is suggested to 
promote a mesenchymal morphology and contribute to ovarian cancer progression. It has also been 
mentioned that the overexpression of let-7i down-regulated oncogenic proteins such as H-RAS and 
HMGA2 to a significant extent in ovarian cancer cell lines [93]. These data support that deregulated 
miRNAs also might promote ovarian cancer progression by derepressing cancer-associated genes as 
well as by repressing the expression of the genes.  
Table 2. Epigenetically up-regulated genes in ovarian cancer.  
Gene Symbol  Name  Chromosome   Mechanism of Up-Regulation   Reference  
Oncogene or Proto-Oncogenes        
HRAS  v-Ha-ras Harvey rat sarcoma 
viral oncogene homolog 
11p15.5  miRNA (Let-7i)  [93] 
HMGA2  High mobility group AT-hook 2  12q15  miRNA (Let-7i)  [93]  
BCL2  B-cell CLL/lymphoma 2  18q21.3  miRNA (miR-15a and miR-16)  [89]  
BCL3  B-cell CLL/lymphoma 3  19q13.1–q13.2  miRNA (miR-125b)  [91] 
BMI1  BMI1 polycomb ring finger 
oncogene  
10p11.23  miRNA (miR-15a and miR-16)  [89]  
NFKB1(NF-
kappa B1) 
Nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells 1 
4q24  miRNA (miR-9)  [90] 
         
Cancer-Promoting Genes              
SNCG  Synuclein, gamma (breast 
cancer-specific protein 1) 
10q23.2–q23.3  Promoter DNA hypomethylation   [77,78] 
CTCFL(BORIS)  CCCTC-binding factor (zinc 
finger protein)-like  
20q13.31  Promoter DNA hypomethylation   [79] 
CLDN3  Claudin-3  7q11.23  Promoter DNA hypomethylation 
and histone acetylation 
[94] 
      Loss of repressive histone 
methylations 
[86] 
CLDN4  Claudin-4  7q11.23  Promoter DNA hypomethylation, 
histone acetylation  
[95,96] 
            Loss of repressive histone 
methylations 
[86] 
         
Cancer-Associated Genes       
DNAJC15(MCJ)  DnaJ (Hsp40) homolog, 
subfamily C, member 15 
13q14.1  Promoter DNA hypomethylation   [81,82]  
MAL  Mal, T-cell differentiation 
protein  
2cen-q13  Promoter DNA hypomethylation   [83] 
HOXA10  Homeobox A10  7p15.2  Promoter DNA hypomethylation  [84] 
TUBB3  Class III ß -tubulin  16q24.3  Promoter DNA hypomethylation 
and histone acetylation 
[85] 
ARID3B  AT-rich interactive domain 3B   15q24  miRNA (miR-125a)  [92] Int. J. Mol. Sci. 2011, 12                       
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5. Epigenetics of Cancer-Initiating Cells in Ovarian Cancer  
Recently, tumor cell heterogeneity has been explained by the existence of epigenetic variation in 
progenitor cells. This ―epigenetic progenitor model‖ suggests that stem or progenitor cells become 
cancer  cells  following  epigenetic  changes,  highlighting  the  crucial  role  of  epigenetic  alteration  in 
cancer initiation [6].  
Self-renewing  CICs are thought to constitute a small population of cells responsible for  tumor 
formation and maintenance within a tumor [97]. These CICs, first identified in leukemia [98], have 
been  identified  in  several  solid  tumors  including  breast,  brain,  prostate,  head  and  neck,  colon, 
pancreas, lung, liver and melanoma [99]. Ovarian CICs were also identified and isolated in ovarian 
cancer patient ascites [100] and primary ovarian tumors [101,102]. Furthermore, several markers able 
to  define  a  CIC  population  in  primary  ovarian  tumors  have  been  discovered,  for  example,  
CD44
+CD117
+  [101],  CD133
+  [103,104],  CD24
+  [104]  and  CD44
+/MyD88
+  [105].  Recent  studies 
additionally reported that a phenotype of CD44
+CD24
+Epcam
+ is enriched for ovarian CICs [106], and 
aldehyde dehydrogenase-1A1(ALDH1A1)-positive cells are a population with properties of ovarian 
CICs, which are associated with chemoresistance, and down-regulation of ALDH1A can resensitize 
chemotherapy in ovarian cancer [107].  
Since  the  epigenetic  modulation  of  gene  expression  is  central  to  the  maintenance  of  stem  cell 
identity [108], CICs are also likely to be regulated by an epigenetic mechanism. Specifically, it has 
been suggested that bivalent modifications consisting of the coexistence of activating H3K4 methylation 
marks and repressive H3K27 methylation marks silence developmental genes in embryonic stem cells 
while keeping them poised for activation [20]. A bivalent chromatin pattern was also identified in 
pluripotent  embryonic  carcinoma  cells  as  an  epigenetic  mechanism  for  gene  regulation  [109], 
supporting  the  association  of  chromatin  modifications  with  CICs.  It  has  also  been  suggested  that 
miRNAs are involved in the dysregulation of CICs by modulating the pivotal signaling pathways of 
the ―stem cell genes‖, Notch, Hedgehog, Wnt/-catenin, HMGA2, Bcl-2 and Bmi-1 [110]. Recently, 
the expression of CD133, which is one of the cell surface markers for CICs in several cancers, including 
ovarian cancer, was shown to be regulated by DNA methylation (an epigenetic modification) [103], 
supporting the hypothesis that the identity of CICs may be defined by epigenetic modulation of stem 
cellness-related genes. 
6. Epigenetics and Drug Resistance in Ovarian Cancer  
The  standard  chemotherapy  strategy  in  treating  ovarian  cancer  involves  a  combination  of  a 
platinum-  (carboplatin  or  cisplatin)  and  a  taxane-  (paclitaxel  or  docetaxel)  based  therapy. 
Chemoresistance is a major problem that compromises the effects of the current chemotherapies in 
ovarian cancer, and it has been discovered that epigenetic changes in several genes are associated with 
chemoresistance in this type of cancer. Firstly, CpG DNA methylation of the MLH1 mismatch repair 
genes was associated with a relapse of a chemoresistant ovarian tumor [111]. Subsequently, it was 
shown  that  the  silencing  of  SFRP5  (a  Wnt  antagonist)  by  DNA  hypermethylation  was  related  to 
platinum resistance of ovarian cancer [112]. High levels of methylation in the Methylation Controlled 
DNAJ  (MCJ)  gene  resulted  in  loss  of  gene  expression  and  correlated  with  a  poor  response  to Int. J. Mol. Sci. 2011, 12                       
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chemotherapy [82], while the epigenetic inactivation of ASS1 (argininosuccinate synthetase) was also 
associated with resistance to platinum chemotherapy [113]. In addition to a loss of expression due to 
DNA methylation, it was shown that an increase in expression of the MAL (myelin and lymphocyte 
protein) gene is associated with DNA hypomethylation and platinum resistance [83]. Based on the 
association of DNA methylation of specific genes with platinum sensitivity, a global approach to the 
identification of biological pathways implicated in platinum chemoresistance in ovarian cancer cells 
was recently performed [114]. This study showed that the hypermethylation-mediated repression of 
cell adhesion and tight junction pathways and the hypomethylation-mediated activation of the cell 
growth-promoting  pathways,  PI3K/Akt,  TGF-beta  and  cell  cycle  progression,  might  contribute  to 
cisplatin resistance in ovarian cancer cells.  
Several  miRNAs  and  their  predicted  target  mRNAs,  which  are  associated  with  a  response  to 
chemotherapy in ovarian cancer cells, were recently identified [115]. It was reported that miR-214 
induced cisplatin resistance by targeting PTEN [49], that let-7i was a down-regulated tumor suppressor 
gene  in  platinum-resistant  ovarian  tumors  and  that  reduced  let-7i  expression  increased  resistance 
to cisplatin [93]. 
7. Epigenetic Therapy  
Unlike  genetic  changes,  epigenetic  modifications,  including  DNA  methylation  and  histone 
modifications, are reversible, which suggests that such modifications may be promising therapeutic 
targets. Therefore, it may be possible to reverse aberrant gene expression using epigenetic drugs that 
alter DNA methylation and histone modification patterns. Currently, several epigenetic compounds 
have been developed that target the DNA methylation and histone deacetylation enzymes, and these 
have either been approved for use or are being tested in clinical trials (Table 3).  
The most commonly used DNA methyltransferase inhibitors (DNMTi) are nucleoside analogues, 
including  5-aza-cytidine  (5-azaC),  5-aza-2’-deoxycytidine  (5-aza-dC)  and  Zebularine  [116–118]. 
These DNMTi are converted to deoxynucleotide triphosphates intracellularly, and may be incorporated 
into replicating DNA instead of cytosine, thereby trapping DNMT at the sites of the incorporated 
nucleosides.  Importantly,  these  inhibitors  cause  the  loss  of  DNA  methylation  and  result  in  the  
re-expression  of  the  tumor  suppressor  genes  or  the  genes  that  were  aberrantly  silenced  by  DNA 
methylation in cancer cells, which can result ultimately in the inhibition of tumor cell growth or the 
induction of cell differentiation and cancer cell death [116] (Figure 2). Both 5-azaC and 5-aza-dC were 
recently  approved  by  the  U.S.  Food  and  Drug  Administration  (FDA)  for  the  treatment  of 
myelodysplastic syndrome (MDS) [117]. 
In addition to DNA demethylation agents, several drugs that inhibit HDACs are under development 
as promising anti-cancer drugs because histone deacetylation is involved in suppressing critical genes 
such as tumor suppressor genes. HDAC inhibitors (HDACi) are reported to show anti-tumor effects by 
inhibiting cell growth, promoting apoptosis or inhibiting invasion or metastasis. These HDACi-induced 
effects are related to the induction of the cell cycle inhibitor p21, pro-apoptotic genes and E-cadherin, 
which suppress cell invasion and metastasis through promoter hyperacetylation of these genes [118,119] 
(Figure  2).  The  U.S.  FDA  recently  approved  Suberoylanilide  Hydroxamic  Acid  (SAHA)  for  the Int. J. Mol. Sci. 2011, 12                       
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treatment of T-cell cutaneous lymphoma, and several other HDACi are being developed and/or tested 
in clinical trials (Table 3). 
Table 3. Epigenetic therapeutic compounds, approved or under development.  
Epigenetic 
Drugs 
 
Compound 
(Commercial name) 
Target  Status  Indication  Reference 
DNA 
methylation  
Inhibitor 
(DNMTi) 
Nucleoside analog 
5-aza-cytidine 
(Vidaza) 
DNMT  
FDA 
approved 
MDS 
[116–118] 
5-aza-2’-deoxy 
cytidine 
(decitabine) 
DNMT  
FDA 
approved 
MDS 
Zebularine  DNMT      
Non-nucleoside  Hydralazine  DNMT  Phase I   
HDAC 
inhibitor  
(HDACi) 
Hydroxamate  
SAHA  
(Vorinostat) 
Class I, II 
HDACs 
FDA 
approved  
T cell 
cutaenous 
lymphoma 
[116,118, 
119] 
TSA (Tricostatin A) 
Class I, II 
HDACs 
Preclinical   
LBH589 
(Panobinostat) 
Class I, II 
HDACs 
Phase I/II   
PXD101 
(Belinostat) 
Class I, II 
HDACs 
Phase I/II   
PCI-24781 
Class I, II 
HDACs 
Phase I   
Aliphatic acid 
Sodium phenyl 
butyrate 
Class I, IIa 
HDACs 
Phase I/II   
Valproic acid  
Class I, IIa 
HDACs 
Phase I/II   
Cyclic peptide  
FK228 
(Romidepsin) 
HDAC1, 2  Phase I/II   
Benzamide   MGCD0103  Class I   Phase I/II   
Histone 
methyltrans 
ferase 
inhibitors 
(HMTi) 
S-adenosylhomocysteine 
hydrolase inhibitor 
3-Deazaneplanocin 
A (DZNep) 
Polycomb 
group 
proteins  
   
[116,117, 
120] 
Fungal mycotoxin  Chaetocin   SU(VAR)3-9      [121] 
Small molecule 
inhibitor 
BIX-01294  
G9a histone 
methyl 
transferase 
    [122] 
Histone 
demethylase 
inhibitor 
(HDMi) 
Polyamine analog  Polyamine analog 
Histone 
demethylase 
LSD1  
    [123,124] 
Of recent interest is the development of drugs that target enzymes involved in histone methylation 
which  also  play  a  role  in  the  silencing  of  tumor  suppressor  genes  in  cancer  (Table  3).  Recently,  
3-Deazaneplanocin A (DZNep) was reported to deplete polycomb group proteins, inhibit repressive Int. J. Mol. Sci. 2011, 12                       
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histone  methylation  including  H3K27me3  and  H4K20me3,  and  induce  apoptosis  in  breast  cancer 
cells [120]. A small molecule inhibitor was also shown to block H3K9me2 by inhibiting G9a histone 
methyltransferases [122]. On the other hand, polyamine [123] and oligoamine analogs [124] inhibit 
histone demethylases of H3K4, resulting in the up-regulation of aberrantly silenced genes.  
Figure 2. Strategies for epigenetic therapy in cancer treatment. The anti-tumor effects of 
DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi) 
have been demonstrated in preclinical studies and several of these inhibitors are under 
clinical trials for drug development in the treatment of cancer. Recently, a number of novel 
epigenetic  therapies  targeting  histone  methylation  associated  with  the  expression  of  
cancer-associated  genes,  or miRNAs,  have been suggested  for  cancer treatment. These 
epigenetic  therapies  are  expected  to  show  anti-tumor  effects  by  inhibiting  growth  or 
inducing the apoptosis of tumor cells. Moreover, epigenetic therapies hold promise for 
resensitizing  cancer  cells  to  chemotherapy  by  modulating  drug  response  genes  or 
pathways. In addition to targeting tumor cells, targeting CICs by epigenetic therapy is also 
emerging as promising approach in the treatment of cancer. It is expected that the survival, 
or differentiation of CICs, could be regulated by epigenetic therapies.  
 
There appears to be a level of synergy between DNA demethylation and histone acetylation in the 
re-expression of silenced genes in cancer [125] and a type of combination treatment is being tested in a 
clinical trial [126]. As the interactions between the various epigenetic modifications become clearer, 
further combination treatments of DNA and histone modification inhibitors may be investigated as 
promising approaches in the treatment of cancer. Recently, a combined epigenetic therapy, involving 
the histone methyltransferase EZH2 inhibitor and a HDAC inhibitor, was shown to be effective in 
acute myeloid leukemia (AML) cells [127]. In addition, the LSD1 inhibitor inhibited the growth of 
colon cancer when used in combination with a DNMT inhibitor [124]. Furthermore, these epigenetic 
agents can be used in combination with chemotherapy to augment anti-tumor effects. Epigenetic drugs Int. J. Mol. Sci. 2011, 12                       
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can alleviate the resistance to other drugs, such as those used in chemotherapy, through the reactivation 
of DNA repair genes or other drug response genes (Figure 2) [128]. 
Therapeutic  strategies  for  targeting  the  reactivation  of  epigenetically  silenced  tumor  suppressor 
miRNAs  or  for  targeting  CICs  that  are  refractory  in  standard  chemotherapy  are  also  
promising (Figure 2) [129]. As a single miRNA can have multiple targets that are involved in different 
oncogenic pathways, modulating the level of a single miRNA might be effective in the treatment of 
cancer  patients  by  affecting  many  pathways  at  the  same  time.  Also,  targeting  a  consistently 
deregulated miRNA group in several cancers might be a promising strategy in treating the cancer 
patients [13]. In addition, emerging evidence suggests that miRNAs are linked to the regulation of 
CICs [110], therefore, miRNA-targeted interventions may also be useful as anti-cancer therapies in 
addition to correcting the dysregulated expression of tumor suppressor genes or oncogenes in cancer. 
The  miRNA  antagonists  could  be  used  to  inhibit  oncogenic  miRNAs,  while  miRNA  mimics  or 
lentiviral miRNAs have the potential to restore tumor suppressor miRNAs or to regulate stem cell 
genes. However, delivery of these miRNA-based therapeutics to the tumor remains a great challenge.  
In addition to the reactivation of tumor suppressor genes or drug response genes, epigenetic drugs 
have been found to derepress immunogenicity-related genes, such as cancer/testis antigens, which are 
silent in normal cells but are expressed in various malignancies, suggesting that a combination of 
epigenetic therapy and immunotherapy might be useful [128].  
However,  there  are  several  concerns  in  developing  epigenetic  therapies  related  to  the  
non-specificity of these drugs. DNA hypomethylation agents might actually promote the development 
of some tumors, possibly  by inducing chromosomal instability [130,131]. Simultaneous epigenetic 
derepression of oncogenes, or cancer-promoting genes, with the restoration of tumor suppressors by 
epigenetic agents, may be responsible for the poor efficacy or recurrence after epigenetic therapies. 
Therefore, an understanding of the global changes in gene expression that occur after epigenetic drug 
treatment is essential. 
8. Epigenetic Therapy in Ovarian Cancer  
With  the  advances  in  understanding  of  the  molecular  pathogenesis  of  ovarian  cancer,  several 
promising novel targets for therapy have been identified in epithelial ovarian cancer, and the agents 
targeting  them  are  currently  under  development  [2,5].  Among  these  therapeutic  targets,  several, 
including PI3K/Akt and Src signaling are known to be involved in chemotherapy resistance [2]. The 
recurrence of malignancy or the resistance to current therapies is one of the greatest concerns in the 
treatment  of  ovarian  cancer.  In  particular,  epigenetic  inhibitors  hold  promise  for  overcoming 
chemoresistance in ovarian cancer through the restoration of drug response genes and pathways [8]. 
In fact,  it  was  shown  that  the  DNMT  inhibitor,  decitabine,  decreased  cisplatin  resistance  in  both 
ovarian cancer cells and a mouse xenograft through demethylation of the hMLH1 promoter [132]. 
It was  also  demonstrated  that the HDAC inhibitors, PXD101 (belinostat) and  valproic  acid, could 
resensitize  chemotherapy  resistant  ovarian  cancer  cells  [133,134].  Furthermore,  a  combination  of 
decitabine  and  belinostat  treatments  showed  greater  cisplatin  sensitization  of  a  platinum-resistant 
mouse xenograft than either single treatment alone [135]. Based on the preclinical results of DNMT 
inhibitors or HDAC inhibitors, epigenetic drugs are undergoing clinical trial investigations for the Int. J. Mol. Sci. 2011, 12                       
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treatment of recurrent resistant ovarian cancer [136]. Recently, two clinical trials [137,138] provided 
the first clinical evidences that DNA hypomethylation agent can reverse platinum resistance in ovarian 
cancer patients, suggesting the clinical benefits of epigenetic drugs in the treatment of chemoresistant 
or recurrent advanced cancer. In addition to DNMT inhibitors and HDAC inhibitors, several other 
epigenetic  therapies,  including  inhibitors  of  histone  methylation  or  histone  demethylation,  and 
miRNA targeting molecules could be used in the treatment of ovarian cancer in combination with 
chemotherapy  or  other  therapies,  although  the  anti-tumor  effect  of  such  therapies  has  not  yet 
been proven. 
On  the  downside,  epigenetic  drugs  may  simultaneously  derepress  cancer-promoting  genes  or 
oncogenes  and  restore  tumor  suppressor  genes  in  ovarian  cancer.  Growing  evidence  shows  that  
cancer-promoting  genes  or  oncogenes  are  likely  to  be  up-regulated  by  epigenetic  mechanisms  in 
ovarian cancer [8]. By combining the epigenetic treatment which up-regulates cancer-promoting genes 
or oncogenes with other therapies targeting those up-regulated genes, the augmentation of anti-tumor 
effect of epigenetic therapies can be expected. Therefore, it is very important to identify the molecular 
targets,  for which  targeting  by  epigenetic therapy  together  with  other therapies causes a synthetic 
lethality. For example, the combined treatment of therapeutic antibodies targeting membrane proteins 
whose expression could be increased by epigenetic therapy in cancer cells (e.g., claudin-3 or claudin-4 
in ovarian cancer cells) with epigenetic treatment could be a promising approach for the treatment of 
cancer.  Consequently,  a  comprehensive  understanding  of  the  genes  affected,  together  with  a 
knowledge of the global genomic/epigenomic changes in ovarian cancer that occur after epigenetic 
drug treatment would be required to develop a more effective treatment strategy in combination with 
epigenetic therapy.  
9. Conclusions  
Given the high mortality rate for ovarian cancer patients due to difficulties in early detection and 
recurrence after current chemotherapy, the identification of promising therapeutic targets for molecular 
targeted therapy as well as the identification of relevant biomarkers for early detection is an immediate 
and crucial goal. Growing evidence supports the importance of epigenetic changes in tumorigenesis as 
much as the classical, and better known, genetic changes. Moreover, the crucial role of epigenetic 
aberrations during the early stages of tumorigenesis, and their link to CICs suggests that epigenetically 
dysregulated  genes  or  pathways  in  cancer  cells  may  be  promising  targets  for  the  prevention  or 
treatment of cancer. Several cancer-associated genes that play a role in the developmental progression 
of  ovarian  cancer  are  also  epigenetically  regulated.  Even  though  it  is  not  well  established  that 
oncogenes or cancer-promoting genes can be activated by epigenetic mechanisms, a few recent studies 
suggest that several epigenetic modifications, in addition to DNA hypomethylation are also likely to be 
involved in the activation or overexpression of cancer-associated genes. In particular, understanding 
the  epigenetic  derepression  of  oncogenes,  or  cancer-promoting  genes,  would  be  important  for  the 
development  of  epigenetic-based  therapies  used  in  combination  with  other  therapies.  With  the 
development of high-throughput genomic/epigenomic approaches, it is now possible to identify the 
global differences between cancers and normal tissues. Thus, a comprehensive understanding of both 
the genomics and epigenomics of ovarian cancer through the use of integrated approaches should make Int. J. Mol. Sci. 2011, 12                       
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it possible to identify epigenetically activated oncogenes or ovarian cancer-promoting genes. This will 
facilitate the identification of more significant biomarkers and promising novel therapeutic targets for 
ovarian cancer, and consequently, will contribute to the improved detection of ovarian cancer and  
its treatment. 
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